Velcalcetide
From HOP house of papers
(Difference between revisions)
Ossip Groth (Talk | contribs) m (→Wikipedia) |
Ossip Groth (Talk | contribs) m (→Trials) |
||
| (One intermediate revision by one user not shown) | |||
| Line 6: | Line 6: | ||
==Mechanism of action== | ==Mechanism of action== | ||
| − | {{ | + | {{slink| |t=Velcalcetide for secondary hyperparathyroidism – first line|l=http://www.hsric.nihr.ac.uk/topics/velcalcetide-for-secondary-hyperparathyroidism-first-line/|usr=goo}} |
{{tp|p=26290606|t=Critical Cysteine Residues in Both the Calcium-Sensing Receptor and the Allosteric Activator AMG 416 Underlie the Mechanism of Action |pdf=http://molpharm.aspetjournals.org/content/early/2015/08/19/mol.115.098392.full.pdf|usr=|}} | {{tp|p=26290606|t=Critical Cysteine Residues in Both the Calcium-Sensing Receptor and the Allosteric Activator AMG 416 Underlie the Mechanism of Action |pdf=http://molpharm.aspetjournals.org/content/early/2015/08/19/mol.115.098392.full.pdf|usr=|}} | ||
{{tp|p=23674604|t=Pharmacology of AMG 416 (Velcalcetide), a novel peptide agonist of the calcium-sensing receptor, for the treatment of secondary hyperparathyroidism in hemodialysis patients |pdf=|usr=|}} | {{tp|p=23674604|t=Pharmacology of AMG 416 (Velcalcetide), a novel peptide agonist of the calcium-sensing receptor, for the treatment of secondary hyperparathyroidism in hemodialysis patients |pdf=|usr=|}} | ||
| Line 23: | Line 23: | ||
==Trials== | ==Trials== | ||
| − | + | {{slink|t=trials|l=https://www.clinicaltrials.gov/ct2/results?term=%28Etelcalcetide+OR+%28AMG-416+OR+AMG+416+OR+AMG416%29+OR+%28KAI-4169+OR+KAI+4169+OR+KAI4169%29+OR+%28ONO-5163+OR+ONO+5163+OR+ONO5163%29+OR+Telcalcetide+OR+Velcalcetide%29&Search=Search}} | |
==Wikipedia== | ==Wikipedia== | ||
Latest revision as of 06:53, 1 September 2015
- HOP_Nephrology_Index shows all Nephrology topics
- All re-compiled topics
Moremed Velcalcetide Etelcalcetide+OR+{AMG_416}+OR+{KAI_4169}+OR+{ONO_5163}+OR+Telcalcetide+OR+Velcalcetide
Velcalcetide, a novel calcimimetic, is an allosteric activator of casr, the calcium sensitizing receptor and is in development to treat secondary hyperparathyreoidism of chronical renal failure in a way similar to cinacalcet.
Contents |
Mechanism of action
| Weblink noncommercial {{{c}}} |
| Velcalcetide for secondary hyperparathyroidism – first line |
| Journal article, free access |
| GET Critical Cysteine Residues in Both the Calcium-Sensing Receptor and the Allosteric Activator AMG 416 Underlie the Mechanism of Action Extract PDF direct |
| Journal article, free access |
| GET Pharmacology of AMG 416 (Velcalcetide), a novel peptide agonist of the calcium-sensing receptor, for the treatment of secondary hyperparathyroidism in hemodialysis patients Extract [ PDF direct] |
| Journal article, free access |
| GET Comparison of AMG 416 and cinacalcet in rodent models of uremia Extract PDF direct |
| Journal article, free access |
| GET Velcalcetide (AMG 416), a novel peptide agonist of the calcium-sensing receptor, reduces serum parathyroid hormone and FGF23 levels in healthy male subjects Extract PDF direct |
| Journal article, free access |
| GET AMG 416 (velcalcetide) is a novel peptide for the treatment of secondary hyperparathyroidism in a single-dose study in hemodialysis patients Extract [ PDF direct] |
Mentioned in Fulltext
| Journal article, free access |
| GET The use of fibroblast growth factor 23 testing in patients with kidney disease Extract PDF direct |
| Journal article, free access |
| GET Longitudinal FGF23 and Klotho axis characterization in children treated with chronic peritoneal dialysis Extract PDF direct |
| Journal article, free access |
| GET Calcimimetics and outcomes in CKD Extract PDF direct |
Trials
| Weblink noncommercial {{{c}}} |
| trials |
Wikipedia
| Wikipedia |
| en-wiki |
Books
